European stakeholder perspectives on challenges to rare disease drug development – a qualitative study

IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Sarala Joshi, Jessica Chen, M. Sultan, Shefali Singh, Syed Abedi, Sifan Zheng
{"title":"European stakeholder perspectives on challenges to rare disease drug development – a qualitative study","authors":"Sarala Joshi, Jessica Chen, M. Sultan, Shefali Singh, Syed Abedi, Sifan Zheng","doi":"10.1080/21678707.2021.1953469","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background The multifaceted challenges of rare disease research remain, leaving a large proportion of rare disease patients without treatment options. This study aims to identify the challenges of rare disease drug development. Research design & methods Ten semi-structured interviews were carried out with a range of stakeholders. Thematic analysis was conducted to identify common and important themes. Results Four overarching themes of stakeholder engagement, regulatory structure, data, and patient support were identified, encompassing fifteen subthemes. Conclusion The presence of an active patient group is a significant factor in reducing barriers to rare diseases treatment development. Effective collaboration between the various stakeholders of rare disease research is crucial.","PeriodicalId":12118,"journal":{"name":"Expert Opinion on Orphan Drugs","volume":"9 1","pages":"181 - 188"},"PeriodicalIF":0.8000,"publicationDate":"2021-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21678707.2021.1953469","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Orphan Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678707.2021.1953469","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

ABSTRACT Background The multifaceted challenges of rare disease research remain, leaving a large proportion of rare disease patients without treatment options. This study aims to identify the challenges of rare disease drug development. Research design & methods Ten semi-structured interviews were carried out with a range of stakeholders. Thematic analysis was conducted to identify common and important themes. Results Four overarching themes of stakeholder engagement, regulatory structure, data, and patient support were identified, encompassing fifteen subthemes. Conclusion The presence of an active patient group is a significant factor in reducing barriers to rare diseases treatment development. Effective collaboration between the various stakeholders of rare disease research is crucial.
欧洲利益相关者对罕见病药物开发挑战的看法——一项定性研究
摘要背景罕见病研究仍然面临多方面的挑战,使很大一部分罕见病患者没有治疗选择。本研究旨在确定罕见病药物开发的挑战。研究设计与方法对一系列利益相关者进行了10次半结构化访谈。进行了专题分析,以确定共同和重要的主题。结果确定了利益相关者参与、监管结构、数据和患者支持四个总体主题,包括15个子主题。结论活跃患者群体的存在是减少罕见病治疗发展障碍的重要因素。罕见病研究的各个利益相关者之间的有效合作至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Opinion on Orphan Drugs
Expert Opinion on Orphan Drugs PHARMACOLOGY & PHARMACY-
CiteScore
2.30
自引率
0.00%
发文量
8
期刊介绍: Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信